SML0702
MRT67307 盐酸盐
≥98% (HPLC), IKKe and TBK-1 inhibitor, powder
别名:
N-[3-[[5-环丙基-2-[[3-（4-吗啉基甲基）苯基] 氨基]-4-嘧啶基] 氨基] 丙基]-环丁基甲酰胺 盐酸盐
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C26H36N6O2 · xHCl
化学文摘社编号:
分子量:
464.60 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77
产品名称
MRT67307 盐酸盐, ≥98% (HPLC)
SMILES string
N5(CCOCC5)Cc1cc(ccc1)Nc2nc(c(cn2)C4CC4)NCCCNC(=O)C3CCC3
InChI
1S/C26H36N6O2/c33-25(21-5-2-6-21)28-11-3-10-27-24-23(20-8-9-20)17-29-26(31-24)30-22-7-1-4-19(16-22)18-32-12-14-34-15-13-32/h1,4,7,16-17,20-21H,2-3,5-6,8-15,18H2,(H,28,33)(H2,27,29,30,31)
InChI key
UKBGBACORPRCGG-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to light brown
solubility
H2O: 15 mg/mL, clear
storage temp.
2-8°C
Quality Level
Application
MRT67307 盐酸盐已用于研究其对 LPS（脂多糖）诱导溶酶体管状结构的影响。
Biochem/physiol Actions
MRT67307 是 IKKe 和 TBK-1 的双重抑制剂。
MRT67307 是 IKKe 和 TBK-1 的双重抑制剂。IKKe 和 TBK-1 介导干扰素调节因子 3 (IRF3) 的磷酸化。
MRT67307 是氨基嘧啶衍生物，IC 50 值为 19。已知其可诱导 TLR（toll 样受体）介导的抗炎细胞因子生成。此外，MRT67307 还可预防促炎相关细胞因子的分泌。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies.
Hasan M and Nan Y
Pharmacological Research, 111, 336-342 (2016)
Zachary P Guinn et al.
Immunobiology, 224(4), 565-574 (2019-05-11)
IFN-γ produced during viral infections activates the IFN-γ receptor (IFNGR) complex for STAT1 transcriptional activity leading to expression of Interferon Regulatory Factors (IRF). Simultaneous activation of TBK/IKKε via TLR3 during viral infections activates the transcription factor IRF3. Together these transcription factors
Daniel P.
The Inhibitor Index: A Desk Reference on Enzyme Inhibitors, Receptor Antagonists, Drugs, Toxins, Poisons, Biologics, and Therapeutic Leads (2017)
mTOR controls lysosome tubulation and antigen presentation in macrophages and dendritic cells.
Saric A, et al.
Molecular Biology of the Cell, 27(2), 321-333 (2016)
Nadia Carvalho Lima et al.
International journal of molecular sciences, 21(9) (2020-05-07)
Selective FGFR inhibitors such as infigratinib (BGJ398) and erdafitinib (JNJ-42756493) have been evaluated in clinical trials for cancers with FGFR3 molecular alterations, particularly in urothelial carcinoma patients. However, a substantial proportion of these patients (up to 50%) display intrinsic resistance
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持